Education
About Us
Working with TipRanks
Follow Us
Otsuka Holdings Co Ltd (OTSKY)
OTHER OTC:OTSKY
Top Page
Otsuka Holdings Co
(OTC:OTSKY)
72Outperform
Otsuka Holdings Co (OTSKY) vs. S&P 500 (SPY)
Market Cap
$25.98B
Dividend Yield1%
Average Volume (3M)3.25K
Price to Earnings (P/E)11.4
Beta (1Y)0.34
Revenue Growth7.25%
EPS Growth153.13%
CountryUS
Employees35,338
SectorHealthcare
Sector Strength66
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)2.10
Shares Outstanding1,104,049,400
10 Day Avg. Volume9,748
30 Day Avg. Volume3,249
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)N/A
Price to Sales (P/S)1.40
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Otsuka Holdings Co Business Overview & Revenue Model
Company DescriptionOtsuka Holdings Co., Ltd. is a Japanese multinational corporation primarily engaged in pharmaceuticals, nutraceuticals, consumer products, and other diversified businesses. The company operates through various subsidiaries, with a strong focus on its Pharmaceutical and Nutraceutical segments. Otsuka is renowned for its innovative products such as Abilify, a prescription medication for treating mental health disorders, and popular consumer brands like Pocari Sweat and Nature Made supplements.
How the Company Makes MoneyOtsuka Holdings Co. generates revenue through its diversified business segments, with a primary focus on pharmaceuticals and nutraceuticals. The Pharmaceutical segment contributes significantly to its earnings, driven by the development, manufacturing, and sale of prescription medications, including its flagship product, Abilify. The Nutraceutical segment provides a steady revenue stream through the sale of functional foods and beverages, dietary supplements, and skincare products, with well-known brands like Pocari Sweat and Nature Made enhancing its market presence. Additionally, strategic partnerships and collaborations in research and development, as well as investments in innovation, play a crucial role in sustaining and expanding its revenue base. The company's global reach and diverse product offerings enable it to tap into various markets, further solidifying its financial performance.
Otsuka Holdings Co Financial Statement Overview
Summary
Otsuka Holdings Co demonstrates strong financial performance with high growth and profitability. The income statement indicates impressive margins and consistent revenue growth. The balance sheet reflects low leverage and a stable capital structure, while cash flow metrics highlight robust liquidity and cash generation.Income Statement
Otsuka Holdings Co has demonstrated impressive growth and profitability in its income statement. The company achieved a Gross Profit Margin of 71.7% in 2024, reflecting efficient cost management. The Net Profit Margin increased to 14.7%, indicating improved profitability. Revenue has grown consistently over recent years, with the latest year showing a significant increase of 15.4%. EBIT and EBITDA margins are also strong at 13.9% and 19.4%, respectively, showcasing robust operating performance.92
Very Positive
Balance Sheet
The balance sheet of Otsuka Holdings Co reflects a strong financial position, characterized by a low Debt-to-Equity Ratio of 0.07, indicating low leverage and financial risk. The company has a solid Return on Equity (ROE) of 12.6%, demonstrating effective use of equity capital to generate profits. The Equity Ratio stands at 73.1%, highlighting a stable capital structure with substantial equity financing.88
Very Positive
Cash Flow
Otsuka Holdings Co exhibits healthy cash flow metrics with a Free Cash Flow Growth Rate of 33.6%, signifying strong liquidity and cash generation capabilities. The Operating Cash Flow to Net Income Ratio is 1.03, indicating efficient cash conversion from earnings. Additionally, the Free Cash Flow to Net Income Ratio is 0.66, reflecting solid free cash flow relative to earnings.85
Very Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 2.18T | 2.33T | 2.02T | 1.74T | 1.50T | 1.42T |
| Gross Profit | |||||
| 1.54T | 1.67T | 1.41T | 1.17T | 1.00T | 983.08B |
| EBIT | |||||
| 317.84B | 323.56B | 139.61B | 220.54B | 154.50B | 198.58B |
| EBITDA | |||||
| 259.41B | 452.62B | 246.96B | 279.83B | 231.43B | 291.03B |
| Net Income Common Stockholders | |||||
| 126.82B | 343.12B | 121.62B | 133.91B | 125.46B | 148.14B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 350.88B | 458.08B | 529.40B | 489.12B | 430.76B | 401.77B |
| Total Assets | |||||
| 1.46T | 3.74T | 3.36T | 3.10T | 2.82T | 2.63T |
| Total Debt | |||||
| 136.29B | 189.38B | 214.19B | 194.16B | 212.45B | 226.08B |
| Net Debt | |||||
| -164.38B | -236.79B | -299.15B | -277.47B | -198.23B | -130.77B |
| Total Liabilities | |||||
| 509.92B | 961.09B | 924.93B | 840.17B | 775.73B | 744.38B |
| Stockholders Equity | |||||
| 936.29B | 2.73T | 2.39T | 2.23T | 2.01T | 1.85T |
| Cash Flow | Free Cash Flow | ||||
| 166.55B | 225.28B | 168.56B | 104.06B | 115.71B | 134.96B |
| Operating Cash Flow | |||||
| 302.74B | 354.64B | 283.23B | 211.85B | 228.86B | 232.84B |
| Investing Cash Flow | |||||
| -295.42B | -265.79B | -190.54B | -81.58B | -95.29B | -99.86B |
| Financing Cash Flow | |||||
| -39.56B | -189.37B | -60.26B | -95.47B | -95.84B | -104.93B |
Otsuka Holdings Co Technical Analysis
Negative
23.46
Price Trends
25.32
Negative
26.34
Negative
26.95
Negative
Market Momentum
-0.56
Positive
41.62
Neutral
21.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTSKY, the sentiment is Negative. The current price of 23.46 is below the 20-day moving average (MA) of 25.40, below the 50-day MA of 25.32, and below the 200-day MA of 26.95, indicating a bearish trend. The MACD of -0.56 indicates Positive momentum. The RSI at 41.62 is Neutral, neither overbought nor oversold. The STOCH value of 21.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTSKY.
Otsuka Holdings Co Peers Comparison
Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $25.98B | 11.43 | 13.22% | 1.00% | 7.25% | 153.13% | |
70 Outperform | $17.36B | 10.61 | 10.36% | ― | -1.60% | 39.71% | |
70 Outperform | $125.03B | 21.43 | 7.34% | 2.90% | -4.57% | 2.96% | |
65 Neutral | $71.84B | 22.26 | 19.11% | 4.26% | 6.28% | -47.11% | |
64 Neutral | $103.18B | ― | -39.10% | 4.92% | 7.32% | -214.24% | |
57 Neutral | $5.49B | 26.95 | ― | ― | ― | ||
50 Neutral | $5.14B | 3.10 | -40.94% | 2.95% | 17.94% | 2.00% |
* Healthcare Sector Average
Performance Comparison
OTSKY
Otsuka Holdings Co
23.46
3.03
14.83%
BIIB
Biogen
116.49
-77.62
-39.99%
BMY
Bristol Myers
48.94
2.10
4.48%
GSK
GlaxoSmithKline
36.45
-2.60
-6.66%
GRFS
Grifols SA
7.01
0.71
11.27%
SNY
Sanofi
50.93
5.17
11.30%
Otsuka Holdings Co Earnings Call Summary
Earnings Call Date: Feb 14, 2025 | % Change Since: -11.54% | Next Earnings Date: May 9, 2025
Earnings Call Sentiment Positive
The earnings call presented a strong overall performance in both pharmaceutical and nutraceutical segments with significant revenue and profit growth, and positive strategic expansions such as the acquisition for drug discovery. However, there were challenges such as impairment losses and increased SG&A expenses.Highlights
Significant Revenue and Profit Growth
Revenue increased by 17.0% to JPY 1,108.9 billion, and business profit grew by 37.8% to JPY 213.6 billion year-on-year, highlighting strong performance in pharmaceutical and nutraceutical segments.
Nutraceutical Business Expansion
The Nutraceutical business achieved over 20% growth, with revenue increasing in all three categories, notably For Women's Health at 56.9% and For Healthier Life at 25.5%.
Pharmaceutical Business Growth
Revenue in the pharmaceutical business increased by 17.9% year-on-year to JPY 766.7 billion, with significant contributions from products like REXULTI and LONSURF.
Upward Revision of Financial Forecast
The full-year revenue forecast was revised up by JPY 175 billion to JPY 2,315 billion, and business profit was revised up by JPY 60 billion to JPY 390 billion.
Acquisition for Drug Discovery
Announcement of the acquisition of a company in Boston for drug discovery technology, indicating strategic expansion.
Lowlights
Impairment Loss Impact
Operating profit was impacted by an impairment loss on AVP-786, which led to strategic discontinuation of its development.
Decrease in Milestone Revenue
Upfront milestone and royalty revenue decreased to JPY 41.8 billion due to lower sales milestone income compared to the previous year.
Increase in SG&A Expenses
SG&A expenses increased due to higher promotion expenses, impacting overall cost management.
Company Guidance
During the Q2 2024 earnings call for 4578.T, significant financial growth was highlighted, with revenue increasing by 17.0% to JPY 1,108.9 billion and business profit rising by 37.8% to JPY 213.6 billion year-on-year, driven by strong performance in pharmaceutical and nutraceutical segments. Despite an impairment loss on AVP-786 affecting operating profit, net profit climbed by 5.1% due to finance income. The pharmaceutical business saw revenue increase by 17.9% to JPY 766.7 billion, bolstered by products like ABILIFY MAINTENA and JYNARQUE, while LONSURF achieved significant gains through colorectal cancer treatment guidelines endorsements. Nutraceuticals experienced over 20% growth, with revenue reaching JPY 271.8 billion, fueled by a 56.9% rise in the For Women's Health category. The company revised its full-year forecast, raising revenue expectations by JPY 175 billion to JPY 2,315 billion and business profit projections by JPY 60 billion to JPY 390 billion, aiming to maintain momentum through strategic investments and addressing social issues.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.